ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0204

Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents

Soo Min Ahn1, Jonggi Choi2, Byong Duk Ye2, Suk-Kyun Yang2, Ji Seon Oh3, Yong-Gil Kim2, Chang-Keun Lee2, Bin Yoo1, Sang Hyoung Park2 and Seokchan Hong2, 1ASAN MEDICAL CENTER, Seoul, South Korea, 2Asan Medical Center, Seoul, Republic of Korea, 3Asan Medical Center, Ulsan, Republic of Korea

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Infection, Tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Prophylactic anti-viral therapy is required in patients with hepatitis B virus (HBV) infection receiving biologics because of the high risk of HBV reactivation. However, it is unclear when to start biologics after anti-viral prophylaxis. We investigated the risk of HBV reactivation according to the timing of biologics initiation after anti-HBV prophylaxis in IMID patients with HBV infection.

Methods: We retrospectively evaluated the incidence of HBV reactivation in IMID patients who received biologics between July 2005 and April 2020. The patients were divided into two groups (“within 1-week ” vs. “after 1-week”) according to the timing of biologics initiation after anti-HBV prophylaxis. The cumulative probabilities and factors associated with HBV reactivation were evaluated.

Results: A total of 60 hepatitis B surface antigen-positive patients with IMID received biologics (within 1-week group, n = 23 [38%]; after 1-week group, n = 37 [62%]). During a median follow-up of 34 months (interquartile range, 20–74), three (5%) patients developed HBV reactivation. In the univariate analysis, the timing of biologics after HBV prophylaxis was not significantly associated with the risk of HBV reactivation (hazard ratio, 0.657; 95% confidence interval, 0.059–7.327; p = 0.733). The cumulative probabilities of HBV reactivation did not significantly differ according to the timing of biologics as well (p = 0.731).

Conclusion: The risk of HBV reactivation was not significantly associated with the timing of biologics administration after anti-HBV prophylaxis. Thus, biologics may be initiated early in patients with IMID under prophylactic treatment for HBV.


Disclosures: S. Ahn, None; J. Choi, None; B. Ye, None; S. Yang, None; J. Oh, None; Y. Kim, None; C. Lee, None; B. Yoo, None; S. Park, None; S. Hong, None.

To cite this abstract in AMA style:

Ahn S, Choi J, Ye B, Yang S, Oh J, Kim Y, Lee C, Yoo B, Park S, Hong S. Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/risk-of-hepatitis-b-virus-reactivation-in-patients-with-immune-mediated-inflammatory-diseases-receiving-biologics-focus-on-the-timing-of-biologics-after-prophylactic-anti-viral-agents/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-hepatitis-b-virus-reactivation-in-patients-with-immune-mediated-inflammatory-diseases-receiving-biologics-focus-on-the-timing-of-biologics-after-prophylactic-anti-viral-agents/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences